ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,055Medicare Part D Prescriptions Filled, Including Refills

Rank: 14 out of 609

$1.31M Total Retail Price of All Prescriptions

Rank: 8 out of 609

439 Patients Receiving at Least One Drug in Part D
65%Patients 65 Years and Older
73% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Jersey
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 439 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

5% of this provider’s 439 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

1% of this provider’s 8,042 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

55% of this provider’s prescriptions were for brand-name drugs, compared to an average of 36%.

Prescription Price

$108 was the average price of a prescription from this provider, compared to $117 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Jersey
METFORMIN HCL 522 311 1 10
CRESTOR 446 253 2 16
DIOVAN HCT 423 254 3 31
BYSTOLIC 411 275 4 71
SIMVASTATIN 403 290 5 1
GLIMEPIRIDE 401 269 6 53
ONGLYZA 385 262 10 7 178
LANTUS SOLOSTAR 364 209 8 63
AMLODIPINE BESYLATE 278 180 9 2
ATORVASTATIN CALCIUM 230 150 10 6
LEVOTHYROXINE SODIUM 209 140 11 7
JANUVIA 202 158 12 34
CLOPIDOGREL 197 125 13 17
HUMALOG 186 71 14 117
KOMBIGLYZE XR 172 96 15 339
BENICAR HCT 172 149 15 232
FUROSEMIDE 169 132 17 4
ZOLPIDEM TARTRATE 168 122 18 18
PEN NEEDLE 164 102 19 79
PLAVIX 163 120 20 25
ATELVIA 162 147 21 188
LEVEMIR FLEXPEN 160 91 22 167
ZETIA 157 81 23 89
CARVEDILOL 153 113 24 14
LOSARTAN-HYDROCHLOROTHIAZIDE 145 98 25 69
ENABLEX 143 78 26 110
DONEPEZIL HCL 137 137 27 22
NEXIUM 135 98 28 13
DIOVAN 135 96 28 15
NOVOLOG FLEXPEN 116 67 30 122
ENDOCET 110 56 S2 31 45
OMEPRAZOLE 108 63 32 3
HUMALOG MIX 75-25 97 81 33 285
UNIFINE PENTIPS 97 70 33 248
EXFORGE 91 78 35 214
SINGULAIR 90 47 36 78
VYTORIN 80 48 37 255
LIPITOR 80 53 37 47
VALSARTAN-HYDROCHLOROTHIAZIDE 78 50 39 309
LYRICA 78 54 39 90
PRAVASTATIN SODIUM 76 62 41 35
ALLOPURINOL 75 51 42 75
BIDIL 73 61 43 417
HUMALOG MIX 50-50 69 51 44 425
HYDROCHLOROTHIAZIDE 68 57 45 20
LOVAZA 67 52 46 73
METOPROLOL TARTRATE 66 57 47 9
BYETTA 66 31 47 303
SPIRONOLACTONE 61 33 49 105
IBUPROFEN 61 26 49 103
LOSARTAN POTASSIUM 55 27 51 24
AZITHROMYCIN 52 32 52 67
PRANDIN 51 34 53 181
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 9, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.